

Response at 3 months to insulin dose decisions made at exenatide initiation in the ABCD nationwide exenatide audit

Dr Ken Yan Thong, B Jose, ML Cull, A Mills, S Thozhukat, A Rigby, C Walton, REJ Ryder

on behalf of the ABCD nationwide exenatide audit contributors

EASD 46th Annual Meeting, Stockholm, Sep 22 2010

Acknowledgment

 The ABCD nationwide exenatide audit is an independent audit supported by an unrestricted grant from Eli Lilly Ltd



Exenatide and Insulin


- Exenatide, a GLP-1 agonist, is able to improve glycaemic control and promote weight loss in type 2 diabetes
- It is not licensed for use in combination with insulin
- Some obese patients on insulin may have been trialled on exenatide first if this was previously available



 In December 2008, the Association of British Clinical Diabetologists launched a nationwide audit on exenatide in real clinical use

- 315 contributors
- 126 centres
- 6717 patients







 In the audit, many patients were on insulin at exenatide initiation

- Some had their insulin continued
 - Insulin dose unchanged
 - Insulin dose reduced
- Some had their insulin stopped




- Possible reasons for stopping or reducing insulin:
 - Abide by licensing of exenatide use (stopping exenatide)
 - Promote weight loss
 - ?Insulin-sparing
 - Avoid hypoglycaemia

- Possible reasons for continuing insulin at unchanged doses
 - Avoid worsening glycaemic control



 We chose to examine the response at 3 months to insulin dose decisions made at exenatide initiation





Findings 1

 1246/3673 (33.9%) of patients studied were on insulin at exenatide initiation in the ABCD exenatide audit

Of these patients, 319/1246 (25.6%) had their insulin stopped




HbA1c and weight responses with exenatide at 3 months – non-insulin and insulin groups




Baseline vs 3 month HbA1c with exenatide treatment comparing groups of insulin use






Baseline vs 3 month weight with exenatide treatment comparing groups of insulin use





HbA1c and weight changes at 3 months with exenatide comparing groups of insulin use





Findings 2

 Patients who continued insulin achieved further glycaemic reduction of 0.51%, and weight loss of 4.6 kg at 3 months

 Non-insulin patients obtained the most Hba1c benefit but the least weight benefit


 Patients who stopped insulin had the least (none) HbA1c benefit but the most weight benefit

HbA1c and weight responses with exenatide among insulin dose change groups




Baseline vs 3 month HbA1c comparing groups of insulin use with exenatide






Baseline vs 3 month HbA1c comparing insulin dose change groups with exenatide






Baseline vs 3 month weight comparing insulin dose change groups with exenatide






HbA1c and weight changes at 3 months comparing insulin dose change groups with exenatide






Baseline vs 3 month HbA1c comparing insulin dose change groups with exenatide





Correlation between insulin dose reduction and HbA1c change






Percentage insulin dose reduction of total daily dose

Correlation between insulin dose reduction and weight change





Percentage insulin dose reduction of total daily dose

Findings 3

 Weight reduction, but not HbA1c change, correlated with insulin dose reduction

 There was no clear threshold whereby HbA1c or weight was affected, except when compared with insulin being stopped completely




Predictors of glycaemic deterioration when insulin was stopped at exenatide initiation




Baseline vs 3 month HbA1c comparing groups of insulin use with exenatide





HbA1c change at 3 months after exenatide start in insulin stopped group





HbA1c change after insulin stopped

Groups of HbA1c represent changes of +0.5%

Predictors of glycaemic deterioration in patients stopping insulin – multivariate analysis

Independent predictors:

_	- Lower baseline HbA1c			p<0.001	


Higher weight loss at 3 months
 p=0.001

Higher tertile of total insulin dose p=0.009

 Diabetes duration, SU/TZD reduction, use and stopping of long acting insulin did not reach significance

Baseline HbA1c as a predictor of glycaemic deterioration among patients who stopped insulin after exenatide start






A lower baseline HbA1c predicted an HbA1c deterioration or a higher baseline HbA1c predicted an HbA1c improvement

3 month weight loss as a predictor of glycaemic deterioration among patients who stopped insulin after exenatide start





Insulin dose as a predictor of glycaemic deterioration among patients who stopped insulin after exenatide start



	Tertile 1	Tertile 2	Tertile 3
Mean dose	30 U/day	69 U/day	174 U/day
Range	4 to 48 U/day	50 to 99 U/day	100 to 1120 U/day
Mean HbA1c change	-0.73%	+0.10%	+0.60%



Findings 4

- When insulin was stopped at exenatide initiation, nearly half of the patients had worsening HbA1c
 - this is in the background of already suboptimal glycaemic control
- Predictors of glycaemic worsening were a lower baseline HbA1c, higher amount of weight loss at 3 months and a higher total daily insulin dose.

Exenatide and Insulin: Overall Conclusion



- The addition of exenatide to insulin led to further glycaemic improvement and weight loss
- Reducing or stopping insulin at exenatide initiation increased weight loss but at the expense of glycaemic control
- When insulin treatment was substituted by exenatide, a significant proportion of patients had worsening glycaemic control
- Practical conclusion don't stop insulin when starting exenatide – aim to wean off insulin in the appropriate patients instead

ABCD nationwide exenatide audit contributors

The following are those whom we know about.

ABCD nationwide exenatide audit project steering group: Ryder REJ, Walton C, Rowles S, Adamson K, Dove D, Thozhukat S

ABCD nationwide exenatide audit – initial setup, maintenance and nationwide analysis: Ryder REJ, Walton C, Winocour P, Cull ML, Jose B, Sukumar N, Mills AP, Sands K, Shafiq W, Rigby A, Thozhukat S, Thong K. Statistician: Blann A.

Addenbrookes Hospital: Adler A, Evans M, Simmons D, O'Rahilly S, Coll T, Farooqi S, Park A. Altnagelvin Area Hospital: Lindsay J, Kelly J. Antrim Area Hospital: Kennedy A, Rooney D. Barnsley Hospital: Uchegbu E. Basildon University Hospital: Mulcahy M, Krishnan L. Basingstoke and North Hampshire NHS Foundation Trust: Guy R, Turner B, Akester K, Lewis G, Harrison O, Tombling S, Lloyd G, Hughes C, Lowe C. Bedford Hospital: Morrish N, Melvin A, Pledger J, Barron R. Bedfordshire & Hertfordshire PGMS, Luton: Rehman T, Sinclair A. Belfast City Hospital: Henry W. Bolton Diabetes Centre: Palin S, Kenz R. Bristol Royal Infirmary: Raghavan R, Phillips S, Bradley K. Bronglais Hospital: Kotonya C, Premawardhana LDKE. Chesterfield Royal Hospital: Mohammad M, Robinson RTCE, MacInerney RM. Chorley & South Ribble Hospital: Rajbhandari SM, Acharya S. City Hospital, Birmingham: Ryder REJ, Basu A, De P, Lee BC, Jose B, Sukumar N, McAloon CJ, Blann A, Mills AP, Cull ML, Lee A, Rawcliffe C, Ryder B, Burbridge W, Irwin S, Cutler J, Zzizinger A, Mehrali T, Bedi T, Stevenson-Mort J. CMMC Foundation Trust, Manchester: Jinadev P, Watts R, Abul-Ainine S, Salahuddin S. Colchester General Hospital: Bodmer C. Conquest Hospital, St Leonards on Sea: Dashora U, Castro E. Countess of Chester: Shulwalia R., Ewins D, Goenka N. County Hospital, Hereford: Lloyd J. Craigavon Area Hospital, Co Armagh: Ritchie C. Daisy Hill hospital, Newry: Adil MM. Derriford Hospital, Plymouth: English P, Viney T, Laird O, Rigley R, Babu A, Blackmore M. Dumfries & Galloway Royal Infirmary: Bell E., Green F, Banerjee S. East Surrey Hospital, Redhill: Foster K, Natarajan G. Eastbourne District Diabetes Centre: Bending J, Afolayan J, Sheppard P. Fairfield Hospital, Bury: Rowles S, Smithurst HJ. Falkirk and District Royal Infirmary: Kelly C, Peden N, Currie J., Buchanan L. Frimley Park Hospital: Eliwe MH, Bingham E, Tringham JR, Furness General, Barrow In Furness: Chuni P, Hay C, Narayan S, Krishnan S, Gartnavel General Hospital: Small M, Jones G, McGrane D, Sainsbury G. George Eliot Hospital Nuneaton: Shaikh S, Patel V. Good Hope Hospital, Sutton Coldfield: Jones SL, Milles JJ, Griffiths U, Colloby M, Harold C, Rangan S, Morrison J. Glasgow Royal Infirmary, Fisher M, McGrane D. Great Western, Swindon: Govindan J, Price P, Ahmed S, Gardner A. Guys & St Thomas Hospital, London: Brackenbridge A, Reid A, Piper-Smith J, Preston J. Hammersmith and Charing Cross: Field BCT, Dornhorst A. Harrogate Hospital: Hammond P, Harrich Leville Mills (1998) Thirumurugan E, Heartlands Hospital, Birmingham: John R, Patel M, Ulnaf S, Begum S. Hillingdon Hospital, Uxbridge: Edwards M, Doolittle H, Currie A, O'Sullivan S, Lillystone R. Hinchinbrooke Hospital, Huntingdon: Mathews AA. Hull Royal Infirmary: Walton C, Ng B, Kumar BK, Bosomworth A, Ipswich Hospital: Srinath A, Parkinson C, Fowler D, Morris D, Rayman G, Scott A. James Paget Hospital, Great Yarmouth: Grinnell F, Huston N, MacMillian C. King's College Hospital, London: Lee M, Amiel S, Nathan Y. Kingston Hospital: Oldfield M, Htay T, Lagan Valley Hospital, Lisburn: Au S, Turtle EJ. Leicester General Hospital: Tarigopula G, Braithwaite J, Kong M-F, Jackson S, Gregory R. Leicester Royal Infirmary: Nisal K, Gallagher A, Davies MJ, McNally PG, Lawrence IG Lincoln County: Sands K. London Medical: King L, Abraham R, Tomeu J. Mayday University Hospital, Croydon: Prentice M. Medway Maritime Hospital, Gillingham: Scobie IN. Monklands Hospital, Airdrie: Sandeep T. Morriston Hospital, Swansea: Stephens JW. Newcastle General: Taylor R. New Cross Hospital, Wolverhampton: Singh BM, Nayak UA, Govindan J, Kalupahana DN Newham University Hospital, London: Gelding S, Rayanagoudar G.. Ninewells, Dundee: Petrie J, MAI-Dahlaki. Nobles Hospital, Isle of Man: Khan EG, Krishnan A, Clark J, Thondam S. North Manchester General Hospital: Rathur H, Savage M, Wiles P, Prakash P. North Tees & Hartlepool Trust: MacLeod J, Anthony S, Mehaffy J. North Wales NHS Trust, Wrexham: White H. Northampton General Hospital Htike ZZ, Kilvert A, Mtemererwa B, Nisal K, Fox C, Rippin J. Bromley PCT: Casiglia D. Pinderfields General, Wakefield: Nagi DK. Poole Hospital NHS Foundation Trust: Masding M, Osborne K, Wallace P. PRH, Haywards Heath: Smith A, Mabrook J. Prince Philip Hospital, Llanelli: Williams M, Aggarwal N. Princess Royal, Bromley: Lulsegged A. Queen Alexandra, Portsmouth: Cranston I. Queen Elizabeth II Hospital, Welwyn Garden City: Winocour PH. Darzy K, Reddy M. Queen's Hospital, Burton: Benn J. Raigmore Hospital, Inverness: McLaren L. Rotherham General: Franke B. Royal Berkshire Hospital, Reading: Simpson H, Reddy N, Barber T. Royal Blackburn Hospital: Astin J, Faina J, Whalley G, Ramtoola S, Jones G, Wilkinson R. Royal Bournemouth: Richards J, Richardson T. Royal Cornwall Hospital, Treliske: Fox T., Foote J, Browne D, Pinkney J Royal Devon & Exeter: Bowman P, Hattersley A, Vadiya B. Royal Glamorgan Hospital, Llantrisant: Evans P. Royal Gwent Hospital, Newport: Obuobie K. Royal Infirmary of Edinburgh: Jaap A, Noh R, Richards M. Royal Liverpool University Hospital: Vora J, Brake J. Royal Oldham Hospital: Mishra BM. Royal Surrey County Hospital, Guildford: Hordern V. Royal United Hospitals, Bath: Higgs E, Gouni R, Taylor P, Wylie S, Hall B, Hillier N, Neathercote D. RSCH, Brighton: Quin J, Robinson N, Sandwell Hospital, West Bromwich: Ibrahim H, Robertson D, Davies P, Banerjee P, Li YK, Wong KH, Barker N, Dhallu J, Farell D., R.M. Igbal Scunthorpe General: Moisey R, Malik M, Dromgoole P, Elmalti A. Selly Oak Hospital, Birmingham: Creely S, Gough S, Hanif W. Sheffield Teaching Hospitals: Elliott J, Scott A. Smethwick Health Centre: Pall N, Harrington J. South East CHCP, Glasgow: Carson L-A. Southampton General Hospital: Sharp P, Brown B. Southern General Hospital, Glasgow: Semple C. St John's Hospital, Livingston: Adamson K, Green F. St Mary's Hospital, Isle of Wight: Kaklamanou M, Al-Mrayat M. St Peter's Hospital, Chertsey: Sennik D, Baxter M, Naqvi S, Suresh D, Miras A. Staffordshire DGH, Stafford: Coates P, Daggett P, Green F. Stirling Royal Infirmary: Kelly C, Mackenzie A, Peden N. Bronglais Hospital, Aberystwyth: Kotonya CA. Sunderland Royal: Nayar R, Carey P, Aspray T. Taunton & Somerset: Close C, Andrews R, Douek I, Watson J., Lambert P. Torbay Hospital, Torquay: Paisey R. University Hospital Coventry Warwickshire: Anderson S. Ulster Hospital, Belfast: Brennan U, Satti N, Harper R, Harding J. Victoria Infirmary, Glasgow: Stewart A. Warwick Hospital Rao RK, Gopinathan, Horrocks P. Watford General Hospital: Tharakan G, Simpson K. West Suffolk Hospital, Bury St. Edmunds: Majeed J, Clark J, Wijenaike N, Gurnell E, Hartley L, Abdullah H, Marath H. Western General Hospital, Edinburgh: Aniello L, McKnight JA, Strachen M, Reynolds R, Nyrenda M. Berkshire East PCT: Dove D, Aung T. Whitpps Cross University Hospital, London: Lakhdar A, Manogaraan B. Wirral Teaching Hospital, Upton Wirral: Leong KS, Leong K, Lorains J, Joseph P, Leach J, Fenna I. Whiteabbey Hospital: Andrews J, Strrezlecka A. Wishaw General, Lanarkshire: O'Brien I, Davidson E. Worcestershire Acute Hospitals, Worcester: Newrick P, Jenkins D. Wrexham Maelor: Dixon AN, Munigoti S, Stanaway S, Harvey JN. Wythenshawe Hospital, Manchester: Younis N. Yeovil District Hospital: Bickerton AST, Crocker M, Down S. York Hospital: Jennings P, Hudson N.

Acknowledgment

The ABCD nationwide exenatide audit is an independent audit supported by an unrestricted grant from Eli Lilly Ltd





 Results of exenatide and insulin combination after 3 months:

Poster 861
PS 078 (Incretins and insulin studies)
Thursday 1.30 to 2.30pm